AG真人官方

On 15 Jul 2025, GSK plc repurchased 487,387 ordinary shares (nominal 31录 p) through Merrill Lynch International as part of its on-market buy-back. The shares were bought at 1,401.50-1,493.50 p, giving a volume-weighted average price of 1,423.89 p and an estimated cash cost of 拢6.9 million.

Since the non-discretionary programme began on 4 Jun 2025, GSK has acquired 13,210,173 shares. The company now holds 231,344,556 shares in treasury, equivalent to 5.66 % of total voting rights. Shares outstanding (excluding treasury) stand at 4,084,039,501, which is the denominator investors should use for disclosure calculations under the FCA鈥檚 DTR rules.

The Bank of Nova Scotia (NYSE: BNS) has filed a Preliminary Pricing Supplement (Form 424B2) for an upcoming debt offering of Callable Fixed-Rate Notes due July 28, 2033. Key commercial terms are set at issuance price 100% of principal, semi-annual coupons of 5.10% per annum and a final maturity of eight years. The notes are issued under the Bank鈥檚 Senior Note Program, Series B and qualify as bail-inable senior unsecured obligations under Canadian law.

• Size & denomination: Aggregate principal to be determined on trade date (expected July 24 2025); minimum investment US$1,000 and integral multiples thereof.
• Coupon & accrual: 5.10% fixed, calculated on a 30/360 basis, payable every 28 January and 28 July, starting 28 January 2026.
• Issuer call feature: The Bank may redeem the notes in whole (not in part) on any interest payment date beginning July 2026, with 10 business-day notice. If called, holders receive par plus accrued interest only up to the call date鈥攃reating reinvestment risk.
• Ranking & security: Senior, unsubordinated, unsecured; pari passu with other senior debt but not insured by CDIC or FDIC. Subject to statutory bail-in conversion under the Canada Deposit Insurance Corporation Act, meaning principal and unpaid interest can be converted into common equity or extinguished if regulators trigger resolution powers.
• Distribution: Lead underwriter and affiliate Scotia Capital (USA) Inc. will purchase at par and resell to dealers at up to a 2.00% discount. Net proceeds to the Bank estimated at 鈮�98% of face, before hedging profits.
• Liquidity: No listing on any securities exchange; secondary market making, if any, will be discretionary. Investors should be prepared to hold to maturity.
• Risk highlights: Credit risk of BNS, potential bail-in conversion, call/reinvestment risk, price sensitivity to interest-rate moves, limited liquidity and potential conflicts arising from the Calculation Agent role held by an affiliate.

Additional sections outline Canadian and U.S. tax treatments, circumstances for tax-motivated redemption, and prohibitions on retail sales in the EEA and U.K. The document is preliminary; final pricing supplement may modify terms.

Bolt Projects Holdings, Inc. filed Prospectus Supplement No. 3 on 15 July 2025, updating its April 3 2025 S-1 prospectus. The supplement incorporates a Form 8-K dated 11 July 2025.

Key update: under Item 5.02, the Board appointed Lorne Lucree as a Class II director (term ends 2026 AGM) and Gail Zauder as a Class III director (term ends 2027 AGM), effective immediately. Both directors will:

• Receive cash and equity compensation under the existing Non-Employee Director Compensation Program (details previously disclosed in the 2024 Form 10-K).
• Enter into the company鈥檚 standard indemnification agreement.

No financial statements, earnings data, capital-raising details or strategic transactions are included. The filing is primarily administrative, aimed at keeping the prospectus current for potential securities offerings.

GSK plc鈥檚 14 July 2025 Form 6-K discloses a series of routine PDMR (Persons Discharging Managerial Responsibilities) transactions covering the period 9-11 July 2025. Executives, senior management and non-executive directors acquired Ordinary Shares on the London Stock Exchange and ADSs on the NYSE through three mechanisms: (1) monthly Share Reward Plan purchases, (2) automatic dividend reinvestment on holdings in Share Reward, Deferred Annual Bonus and Performance Share Plans, and (3) dividend reinvestment on personal ISA or ADS accounts.

Key highlights

• CEO Emma Walmsley executed the largest transactions, adding 16 shares (拢14.2073) via the Share Reward Plan, 32 shares (拢14.4447) through dividend reinvestment, 4,377 notional shares (拢14.5450) in the Deferred Bonus Plan and 9,799.561 shares (拢14.5450) in the Performance Share Plan, totalling 鈮�14,225 shares at 拢14.21-14.55.
• CFO Julie Brown purchased 18 physical shares and increased notional holdings by 1,409 shares at 拢14.5450.
• Other Executive Committee members鈥攊ncluding Luke Miels (1,862 shares), David Redfern (1,123 shares) and Tony Wood (1,190 shares)鈥攔ecorded similar dividend-driven increases.
• Non-executive directors acquired small blocks of ADSs at $38.5396 per ADS; Charles Bancroft bought the largest block (364 ADSs).
• All acquisitions were at market prices set by dividend reinvestment or plan rules; no sales were reported.

The filing signals continued equity alignment by leadership but does not announce any strategic, operational or financial changes. Volumes are modest relative to GSK鈥檚 5 billion-plus share count, suggesting negligible direct market impact.

Key development: On 14 July 2025 GSK plc filed a Form 6-K reporting that the US FDA has accepted for review a supplemental application to extend the indication of its RSV vaccine, Arexvy, to adults aged 18-49 who have at least one risk factor for severe RSV.

Market opportunity: GSK estimates roughly 21 million US adults under 50 carry comorbidities such as COPD, asthma or heart disease that heighten RSV risk, materially enlarging the vaccine鈥檚 current target population (50+ at risk).

Clinical support: The filing is supported by Phase IIIb study NCT06389487 (n = 1,458). In adults 18-49 at increased risk, neutralising antibody titres met non-inferiority to those 鈮�60 years and safety/reactogenicity matched earlier Phase III data used for initial approval.

Regulatory timeline: FDA decision is expected in H1 2026. Parallel submissions are underway in the EU and Japan, signalling a coordinated global expansion strategy.

Strategic context: Arexvy already holds approval in >60 countries for adults 鈮�60 and in >50 markets for high-risk adults 50-59. Successful label expansion would secure first-mover advantage in an RSV segment with limited competition and could accelerate revenue growth.

Limitations: The announcement contains no sales guidance; commercial impact remains contingent on regulatory approval, ACIP recommendations and real-world uptake.

GSK plc filed a Form 6-K to disclose daily activity under its ongoing share buyback programme. On 11 July 2025 the company repurchased 486,127 ordinary shares (31 录 p nominal) on the London Stock Exchange at prices between 1,405.50 p and 1,454.50 p, producing a volume-weighted average price of 1,420.61 p. The shares will be held in treasury.

Including this tranche, GSK has bought back 12,239,897 shares since the non-discretionary agreement with Merrill Lynch International commenced on 4 June 2025. Treasury stock now stands at 230,374,280 shares, representing 5.64 % of total voting rights. The company鈥檚 outstanding share count, excluding treasury shares, is 4,085,009,777.

The disclosure also provides granular trade data for regulatory transparency in accordance with the UK FCA鈥檚 Disclosure Guidance and Transparency Rules.